Business and Finance Business and Finance
Sun, February 23, 2025
[ Today @ 02:21 PM ] - MSN
'Maybe I'll just resign': Federal workers react to the mass DOGE email
[ Today @ 02:00 PM ] - MSN
Business Owners Must File BOI Form or Face Stiff Penalties
[ Today @ 12:21 PM ] - MSN
Is H.B. Fuller Company (FUL) The Best 52-Week Low Stock To Buy Now According to Short Sellers?
[ Today @ 12:20 PM ] - MSN
3 Artificial Intelligence (AI) Stocks That I'm Buying and Holding Forever
[ Today @ 11:40 AM ] - MSN
U.S. Companies Scaling Back DEI Efforts Amid Trump's Orders
[ Today @ 11:40 AM ] - MSN
Organon & Co. (OGN): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts
[ Today @ 11:01 AM ] - Insider
I'm a millionaire and my partner makes $60K. I do .. k him to split bills 50-50 because it's not fair.
[ Today @ 11:00 AM ] - Forbes
Men Are Getting Filler Injected Into Their Genitals To Get Larger
[ Today @ 11:00 AM ] - AOL
Forget quiet luxury: America's wealthy 1% are adopting a bolder new approach
[ Today @ 10:41 AM ] - MSN
"Stop wasting cash": Shark Tank investor Kevin O' .. ares the advice he would give to his younger self
[ Today @ 10:41 AM ] - MSN
In auto-centric Michigan, Trump's proposed tariffs polarize a community
[ Today @ 10:41 AM ] - MSN
Abu Dhabi signs groundbreaking agreements with China to strengthen economic, business partnerships
[ Today @ 10:40 AM ] - AOL
Warren Buffett: America's businesses 'usually find a way'
[ Today @ 10:01 AM ] - MSN
Merck & Co., Inc. (MRK): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts
[ Today @ 09:41 AM ] - MSN
Top global stories this week: HSBC, Alibaba, Airbus among notable names
[ Today @ 09:20 AM ] - Kiplinger
Investing in Art: 10 Things You Should Know
[ Today @ 08:20 AM ] - GeekWire
Qualterra raises $4.5M to turn organic waste into carbon-trapping, crop-boosting biochar
[ Today @ 08:20 AM ] - MSN
Atmus Filtration Technologies Inc. (NYSE:ATMU) Q4 2024 Earnings Call Transcript
[ Today @ 07:20 AM ] - MSN
What happens when a company's 'low performers' speak up
[ Today @ 07:00 AM ] - Newsday
Keeping a bank account: A fearful, challenging process for some on Long Island
[ Today @ 07:00 AM ] - Tuko
Can Kenyans Buy Bread with Crypto? Experts Weigh in on Cryptocurrency Adoption and Everyday Use
[ Today @ 06:40 AM ] - MSN
What Brand Is Behind Costco's Kirkland Signature Frozen Lasagna?
[ Today @ 06:21 AM ] - MSN
Got $5,000? 2 Top Growth Stocks to Buy That Could Double Your Money.
[ Today @ 04:40 AM ] - MSN
2 cities tried basic income for formerly incarcer .. ore food secure but struggled to pay for housing.
[ Today @ 04:20 AM ] - businessday
Top 10 African countries with high sovereign wealth funds
[ Today @ 03:41 AM ] - Tuko
Well-off Hong Kong daunted by record deficits
[ Today @ 03:40 AM ] - Forbes
Why Personal Finance Pressures Can Affect Founder Exit Decisions
[ Today @ 01:20 AM ] - MSN
Hong Kong and Singapore lead Asia's drive to cash in on crypto boom
[ Today @ 12:40 AM ] - MSN
St. Paul Brewing worries city's new development plan will mean the end to their business
[ Today @ 12:21 AM ] - Variety
Warren Buffett Says 'It Won't Be Long' Before Greg Abel Succeeds Him as Berkshire Hathaway CEO

Organon & Co. (OGN): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts


Published on 2025-02-23 11:40:49 - MSN
  Print publication without navigation

  • We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where Organon & Co. (NYSE:OGN) stands against the other pharmaceutical stocks.

The article from MSN Money discusses Organon & Co. (OGN), highlighting it as one of the undervalued pharmaceutical stocks recommended for investment by analysts. Organon, which was spun off from Merck in 2021, focuses on women's health, biosimilars, and established brands. Despite facing challenges like patent expirations and generic competition, the company has shown resilience with a diversified portfolio. Analysts are optimistic about Organon due to its potential for growth in the women's health sector, its robust pipeline, and strategic initiatives aimed at expanding its market presence. The stock is considered a bargain with a forward P/E ratio significantly lower than the industry average, suggesting it might be undervalued. The article also mentions that Organon's efforts to reduce debt and improve its financial health are viewed positively by the investment community, making it an attractive option for investors looking for value in the pharmaceutical sector.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/other/organon-co-ogn-among-the-cheap-pharmaceutical-stocks-to-buy-according-to-analysts/ar-AA1zB5gG ]
Contributing Sources